Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $2.1 million.

  • Immunocore Holdings' Gains from Investment Securities rose 455.31% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 786.61%. This contributed to the annual value of -$1.8 million for FY2024, which is 120.50% down from last year.
  • Latest data reveals that Immunocore Holdings reported Gains from Investment Securities of $2.1 million as of Q3 2025, which was up 2.77% from $2.0 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Gains from Investment Securities high stood at $9.5 million for Q1 2024, and its period low was -$1.1 million during Q2 2024.
  • Over the past 3 years, Immunocore Holdings' median Gains from Investment Securities value was $110,000 (recorded in 2023), while the average stood at $1.2 million.
  • The largest annual percentage gain for Immunocore Holdings' Gains from Investment Securities in the last 5 years was 4,435.42% (2024), contrasted with its biggest fall of 347.95% (2024).
  • Immunocore Holdings' Gains from Investment Securities (Quarterly) stood at $757,000 in 2023, then plummeted by 140.03% to -$303,000 in 2024, then soared by 455.31% to $2.1 million in 2025.
  • Its Gains from Investment Securities was $2.1 million in Q3 2025, compared to $2.0 million in Q2 2025 and -$509,000 in Q1 2025.